Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study

This publication has 33 references indexed in Scilit:

• 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
  New England Journal of Medicine, 2008
• Insulin glargine and receptor‐mediated signalling: clinical implications in treating type 2 diabetes
  Diabetes/Metabolism Research and Reviews, 2007
• Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes Across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes Mellitus
  Clinical Therapeutics, 2007
• Comparison of the Mitogenic Potency of Regular Human Insulin and its Analogue Glargine in Normal and Transformed Human Breast Epithelial Cells
  Hormone and Metabolic Research, 2007
• Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir
  Current Medical Research and Opinion, 2006
• A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes
  Diabetes/Metabolism Research and Reviews, 2005
• Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells
  American Journal of Physiology-Endocrinology and Metabolism, 2004
• A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes
  Hormone and Metabolic Research, 2003
• UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis
  Diabetologia, 2001
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  The Lancet, 1998